Gainers

• Jasper Therapeutics (NASDAQ:JSPR) stock rose 19.6% to $1.4 during Friday's pre-market session. The company's market cap stands at $32.7 million.
• Quince Therapeutics (NASDAQ:QNCX) stock moved upwards by 18.22% to $0.27. The market value of their outstanding shares is at $12.5 million.
• Immunic (NASDAQ:IMUX) stock moved upwards by 14.92% to $1.0. The market value of their outstanding shares is at $104.6 million.
• Iterum Therapeutics (NASDAQ:ITRM) shares rose 13.16% to $0.33. The market value of their outstanding shares is at $15.3 million.
• NewGenIvf Group (NASDAQ:NIVF) stock rose 9.36% to $0.8.
• IO Biotech (NASDAQ:IOBT) stock moved upwards by 9.33% to $0.39. The market value of their outstanding shares is at $25.5 million.

Losers

• Sensus Healthcare (NASDAQ:SRTS) stock declined by 24.7% to $3.5 during Friday's pre-market session. The company's market cap stands at $76.3 million. As per the news, the Q4 earnings report came out yesterday.
• Vistagen Therapeutics (NASDAQ:VTGN) shares decreased by 15.69% to $0.46. The company's market cap stands at $21.5 million. As per the news, the Q3 earnings report came out yesterday.
• Coherus Oncology (NASDAQ:CHRS) shares fell 14.43% to $1.72. The company's market cap stands at $242.9 million.
• Bio-Rad Laboratories (NYSE:BIO) stock decreased by 12.92% to $254.65. The market value of their outstanding shares is at $7.8 billion. As per the press release, Q4 earnings came out yesterday.
• Onconetix (NASDAQ:ONCO) shares decreased by 11.19% to $0.94. The market value of their outstanding shares is at $1.6 million.
• OKYO Pharma (NASDAQ:OKYO) shares declined by 9.22% to $1.97. The company's market cap stands at $88.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.